Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 577 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vascular Endothelium Clear all
Completed Phase 3 Interventional

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

NCT00001629
View directory record Official record
Conditions
Atherosclerosis, Heart Failure, Congestive, Hypertension, Myocardial Infarction
Interventions
Angiotensin II type 1 receptor antagonists
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Thromboxane Receptor Antagonist to Improve Endothelial Function

NCT03962855
View directory record Official record
Conditions
Cardiovascular Diseases, Vascular Dilation
Interventions
Ifetroban Sodium, Placebo
Drug
Lead sponsor
Jeffrey Rade
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 1 Interventional

A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies

NCT02572687
View directory record Official record
Conditions
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Interventions
Ramucirumab, MEDI4736
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Aged Garlic Extract (AGE) on Improving Coronary Atherosclerosis in People With Type 2 Diabetes Mellitus

NCT03931434
View directory record Official record
Conditions
Coronary Arteriosclerosis, Endothelial Dysfunction, Type 2 Diabetes Mellitus
Interventions
Aged Garlic Extract (AGE), Placebo
Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
30 Years to 75 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Sep 21, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

NCT06892548
View directory record Official record
Conditions
Advanced Lung Cancer
Interventions
BNT324, BNT327
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
17
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension

NCT01672840
View directory record Official record
Conditions
Hypertension
Interventions
5g Cocoa Consumption, 10g Cocoa Consumption
Dietary Supplement
Lead sponsor
Griffin Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Derby, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Body Mass Index on the Hyperemic Response to Regadenoson

NCT00859833
View directory record Official record
Conditions
Obesity, Endothelial Dysfunction, Decreased Vascular Flow
Interventions
Adenosine, Regadenoson
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 88 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of Regular Exercise on Vascular Function and Cardiovascular Risk in a Sedentary Work Force

NCT00246883
View directory record Official record
Conditions
Vascular Formation
Interventions
Exercise
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 21, 2026, 4:03 AM EDT
Terminated No phase listed Observational

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

NCT01994174
View directory record Official record
Conditions
Macular Disease
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Early Phase 1 Interventional

Effects of Tetrahydrobiopterin on Blood Pressure

NCT00208780
View directory record Official record
Conditions
Hypertension
Interventions
Tetrahydrobiopterin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 21, 2026, 4:03 AM EDT
Not listed No phase listed Observational

Prediction of Progression of Coronary Artery Disease (CAD) Using Vascular Profiling of Shear Stress and Wall Morphology

NCT01316159
View directory record Official record
Conditions
Coronary Atherosclerosis, Acute Coronary Syndrome, Percutaneous Coronary Intervention, Endothelial Shear Stress, Arterial Remodeling
Interventions
Not listed
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 15, 2011 · Synced Sep 21, 2026, 4:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Cyclooxygenase Activity in the Endothelial Function of Hypertensive and Hypercholesterolemic Patients

NCT00001742
View directory record Official record
Conditions
Healthy, Hypercholesterolemia, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 4 Interventional

The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease

NCT05009862
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Rivaroxaban 2.5 Mg Oral Tablet, Placebo, Aspirin 81Mg Ec Tab
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 21, 2026, 4:03 AM EDT
Terminated Phase 4 Interventional Results available

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

NCT05139914
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
30 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Sep 21, 2026, 4:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Vascular Function in Adults With Down Syndrome

NCT07630207
View directory record Official record
Conditions
Down Syndrome (Trisomy 21)
Interventions
Not listed
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 35 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 21, 2026, 4:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Vascular Endothelial Function in Postural Tachycardia Syndrome

NCT01308099
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
Blood Pressure and Blood Flow
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 21, 2026, 4:03 AM EDT
Not listed Phase 2Phase 3 Interventional

Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease

NCT02889549
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ticagrelor, clopidogrel
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin

NCT00385931
View directory record Official record
Conditions
Hypertension, Hypercholesterolemia, Dyslipidemia
Interventions
Valsartan and simvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2023 · Synced Sep 21, 2026, 4:03 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Therapeutic Strategies to Reduce Endothelial Ischemia-reperfusion Injury

NCT06825143
View directory record Official record
Conditions
Metabolic Syndrome, Vascular Injury, Ischemic Preconditioning, Endothelial Function (reactive Hyperemia), Endothelial Dysfunction
Interventions
Ischemic preconditioning, Intravenous lactate infusion, No ischemic preconditioning (control), Normal Saline Infusion (Placebo), Ischemic preconditioning and intravenous lactate
Procedure · Drug · Combination Product
Lead sponsor
Gary Van Guilder
Other
Eligibility
18 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gunnison, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 21, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers

NCT04645160
View directory record Official record
Conditions
Cholangiocarcinoma, Bile Duct Neoplasm, Biliary Tract Malignancy
Interventions
Tivozanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME

NCT03321513
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreous aflibercept, Bevacizumab + Deferred Aflibercept Group
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
54
States / cities
Campbell, California • Glendale, California • Loma Linda, California + 46 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

NCT03370991
View directory record Official record
Conditions
Menopause, Elevated Blood Pressure, Hypertension, Endothelial Dysfunction
Interventions
Blueberry Powder, Placebo Powder
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2022 · Synced Sep 21, 2026, 4:03 AM EDT
Terminated Phase 1Phase 2 Interventional

TRF-1101 Assessment in Sickle Cell Disease

NCT00773890
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
TRF-1101, Placebo
Drug
Lead sponsor
TRF Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Augusta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 10, 2009 · Synced Sep 21, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer

NCT00879359
View directory record Official record
Conditions
Endometrial Carcinoma
Interventions
carboplatin, paclitaxel, and bevacizumab
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 21, 2026, 4:03 AM EDT